Type I Natural Killer T-cell receptor (iNKT TCR) (iNKT TCR)

The Type I Natural Killer T-cell receptor (iNKT TCR) is a semi-invariant heterodimeric protein complex essential for the recognition of lipid and glycolipid antigens presented by the CD1d molecule (Godfrey et al., 2004, Nature Reviews Immunology). In humans, the receptor is typically composed of a conserved Vα24-Jα18 alpha chain paired with a Vβ11 beta chain, allowing it to act as a bridge between innate and adaptive immunity (Pellicci et al., 2020, Nature Reviews Immunology). Upon binding to ligands such as alpha-galactosylceramide (α-GalCer), the iNKT TCR triggers the rapid secretion of diverse cytokines, including IFN-γ and IL-4, which can activate downstream effector cells like Natural Killer (NK) cells and Dendritic cells (Brennan et al., 2013, Nature Reviews Immunology). This receptor is a key therapeutic target in oncology, where its activation is used to enhance anti-tumor immune responses, and in autoimmune research, where it is modulated to restore immune homeostasis (ClinicalTrials.gov, 2023). Therapeutic strategies often involve synthetic glycolipid agonists or TCR-engineered cells to harness the potent immunomodulatory capacity of iNKT cells (NCT03897543). However, clinical application must account for potential safety concerns such as cytokine release syndrome and the induction of iNKT cell anergy following repeated stimulation (Giaccone et al., 2002, Clinical Cancer Research).

Other names

Invariant Natural Killer T-cell receptorVα24-Jα18 TCRVα14-Jα18 TCRCD1d-restricted T-cell receptorInvariant NKT cell receptor

Agonist activation of iNKT cells via CD1d-mediated glycolipid presentation